The FDA has granted Breakthrough Therapy Designation to VER-01, a standardized full-spectrum cannabis extract that outperformed placebo and showed better gastrointestinal tolerability than opioids in two Phase 3 randomized controlled trials for chronic low back pain. This is the first cannabis-derived therapy to receive this designation for a pain indication, and it signals a meaningful shift in how the agency is engaging with cannabis-based medicine.
Table of Contents
Cannabis Extract VER-01 Wins FDA Breakthrough Therapy Status: What It Means for Patients With Chronic Back Pain
A full-spectrum cannabis extract just cleared one of the most consequential regulatory hurdles in American medicine. Here is what FDA Breakthrough Therapy Designation actually means, why VER-01 earned it, and what patients and clinicians in Massachusetts and across the country should understand right now.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Chronic low back pain is among the most common reasons patients seek cannabis care at CED Clinic. FDA Breakthrough Therapy Designation for a cannabis-derived product represents a structural shift in regulatory posture, with direct implications for formulary access, physician liability, and the pace of future approvals. Every clinician who works with pain patients should understand this designation and what it does and does not promise.
- What FDA Breakthrough Therapy Designation is and why it matters beyond the headline
- What the two Phase 3 trials showed about VER-01’s efficacy, tolerability, and safety profile
- How VER-01 compares to opioids and why the GI and dependence data matter
- What this does not mean: why VER-01 is not available in the US yet and what the timeline looks like
- What patients with chronic back pain can consider right now, before VER-01 arrives
- The FDA designated VER-01, a standardized full-spectrum cannabis extract from the DKJ127 strain, as a Breakthrough Therapy for chronic low back pain on May 18, 2026.
- Two Phase 3 RCTs (n=820 in the placebo-controlled trial) showed significant pain reduction, improved sleep and physical function, and no evidence of dependence or withdrawal.
- In a direct comparison, VER-01 produced greater pain reduction and better GI tolerability than opioids, without the abuse liability.
- VER-01 is not yet available in the US. A US pivotal trial is underway, with FDA submission projected for 2028.
| Study Name |
Full-spectrum Cannabis sativa DKJ127 extract for chronic low back pain (Phase 3 RCT) Company: Vertanical |
| Study Type | Multicenter, randomized, double-blind, placebo-controlled Phase 3 trial with open-label extension |
| Population | 820 adults with chronic low back pain (394 VER-01; 426 placebo) |
| Intervention | VER-01 (standardized full-spectrum extract from Cannabis sativa DKJ127) vs. placebo |
| Duration | 12-week double-blind treatment (Phase A) + 6-month open-label extension (Phase B/C) |
| Primary Outcome | Significant pain reduction vs. placebo (primary endpoint met) |
| Secondary Outcomes | Improved sleep disturbances, improved physical function, quality of life |
| Safety | 83.3% VER-01 vs 67.3% placebo treatment-emergent AEs; mostly mild to moderate, self-limiting; no dependence or withdrawal observed |
| Publication | Nature Medicine, September 2025 (doi: 10.1038/s41591-025-03977-0) |
| Regulatory Action | FDA Breakthrough Therapy Designation granted May 18, 2026 (VERTANICAL / FUTRUE Group) |
Chronic low back pain affects an estimated 619 million people worldwide and is the leading cause of disability in the United States. It is also one of the primary drivers of opioid prescribing, with tens of millions of Americans receiving long-term opioid therapy for a condition that opioids often manage poorly and at enormous personal cost.
The FDA’s Breakthrough Therapy Designation is not a rubber stamp. It is a formal acknowledgment that the existing clinical evidence suggests the treatment may offer a substantial improvement over available therapies. Getting there required two Phase 3 RCTs. For a cannabis-derived product, reaching this level of regulatory engagement is itself clinically historic.
VER-01 is not a generic cannabis extract. VERTANICAL developed it from a proprietary Cannabis sativa strain, DKJ127 L, selected specifically for its phytochemical profile relevant to chronic pain. The product is a standardized, pharmaceutical-grade full-spectrum extract, meaning it contains a defined mixture of cannabinoids, terpenes, and other bioactive plant compounds in consistent ratios across every batch. That standardization is precisely what allowed the Phase 3 trials to proceed and what distinguishes VER-01 from the variable-quality products available through most dispensaries.
In the pivotal placebo-controlled trial, 820 adults with chronic low back pain were randomized to VER-01 or placebo for 12 weeks, followed by a 6-month open-label extension. VER-01 met its primary endpoint: statistically significant reductions in pain compared to placebo, with improvements maintained through the extension period. Patients also reported meaningful gains in sleep quality and physical function, two dimensions of chronic pain that conventional analgesia often leaves untreated. In a separate direct-comparison study, VER-01 delivered greater pain relief than opioids while producing better GI tolerability and showing no evidence of dependence or withdrawal on discontinuation.
What FDA Breakthrough Therapy Designation Actually Does
Patients sometimes hear “FDA designation” and assume a drug is approved. It is not. Breakthrough Therapy Designation is a development tool, not a market authorization. What it does is open a channel of intensive FDA guidance during development, prioritize the review process, and signal that the agency considers the preliminary clinical data compelling enough to fast-track its engagement.
The designation also carries weight beyond the bureaucratic. It tells the scientific and medical community that the FDA’s own reviewers looked at two Phase 3 trials of a cannabis-derived product and concluded the evidence is strong enough to deserve special handling. For a treatment category that has spent decades navigating Schedule I barriers to research, that signal is not trivial.
VERTANICAL expects marketing authorization in its first European markets within weeks of this announcement. In the US, the company has launched a separate pivotal Phase 3 trial, with initial data expected in 2027 and a New Drug Application planned for 2028 if results are positive. That is a two-year runway at minimum before US patients can access VER-01 through a conventional prescription.
The Safety Data Deserves a Careful Read
The adverse event numbers look alarming at a glance: 83.3% of VER-01 participants reported treatment-emergent adverse events versus 67.3% in the placebo group. Before drawing conclusions, context matters. The most commonly reported events were dizziness, fatigue, and nausea. These were predominantly mild to moderate in intensity, comparable to the placebo group in overall severity, and largely self-limiting. The trial reported that they occurred mainly during the initial dose-titration period and declined substantially within the first days of treatment.
More clinically meaningful: no patient in the VER-01 arm showed signs of dependence or withdrawal on discontinuation. This stands in direct contrast to opioids, which carry well-documented addiction liability that contributes to one of the most serious public health crises in American history. For patients and prescribers navigating chronic pain with an eye toward long-term safety, that difference is not a minor footnote.
VERTANICAL is careful to note that VER-01’s safety and efficacy data should not be extrapolated to other cannabis products. The specific plant genetics, manufacturing process, and formulation are proprietary. A dispensary product with a similar label is not interchangeable with VER-01, and clinicians should be explicit with patients about that distinction.
What This Means for the Broader Landscape of Cannabis Medicine
This story sits inside a larger moment in US cannabis policy. The DOJ recently issued a final order moving FDA-approved and state-legal cannabis to Schedule III, with an administrative hearing scheduled for June 29 to advance that process across all cannabis products. The TSA updated its guidance in the same week to permit medical cannabis in carry-on and checked bags. And now, for the first time, a cannabis extract has earned Breakthrough Therapy Designation for a pain indication from the same FDA that spent decades treating cannabis research as radioactive.
These are not coincidental headlines. They reflect a converging regulatory and scientific recognition that cannabis-based medicine is producing the kind of rigorous human trial data that earns serious institutional attention. CED Clinic has followed the trajectory of cannabis and opioid reduction closely, and the VER-01 designation represents a step change from observational data to Phase 3 RCT-level regulatory action.
For clinicians in Massachusetts working within the Commonwealth’s medical cannabis program, this reinforces what many practitioners here have observed in practice: carefully selected, properly dosed cannabis can provide meaningful pain relief for a significant subset of patients. The regulatory system is catching up to what the clinical reality has suggested for years. We covered the original Phase 3 trial data when it was published in Nature Medicine last fall. The FDA designation is the next chapter of that story.
VER-01 is a proprietary, pharmaceutical-grade product. Its Phase 3 results cannot be generalized to the full spectrum of cannabis products available in dispensaries or medical programs. A patient purchasing a full-spectrum extract at a Massachusetts dispensary is not getting VER-01, and treating those products as equivalent would be a clinical error.
Breakthrough Therapy Designation also does not guarantee FDA approval. It speeds review and increases FDA engagement, but the NDA process still requires the US Phase 3 trial to succeed. Results are expected in 2027. The pathway to a US prescription is still two or more years out.
How This Fits the Broader Clinical Conversation
Chronic low back pain is a heterogeneous condition. What produces meaningful relief in one patient may do nothing for another, and the mechanisms driving pain can differ considerably across individuals. The opioid epidemic did not emerge from cynicism; it emerged in part from a genuine, widespread need for better analgesia in a patient population that existing tools were failing. Cannabis-based therapies have always held promise in this space precisely because the endocannabinoid system plays a demonstrable role in pain modulation, inflammation, and sleep regulation. The science supporting that pathway has accumulated steadily over two decades.
What has been missing is the kind of large-scale, well-controlled trial evidence that regulators require before formal endorsement. VER-01’s Phase 3 program, with 820 patients in the placebo-controlled arm alone and a direct comparison to opioids, begins to fill that gap in a way that smaller observational studies cannot. The supporting observational data, including a recent University of Pennsylvania study showing a 65% reduction in opioid use among patients given medical cannabis when cost was removed as a barrier, is now being joined by Phase 3 RCT evidence with regulatory backing.
The clinical question for Massachusetts patients and providers is not whether to wait for VER-01. It is whether the existing medical cannabis program, with appropriate physician guidance on formulation, dose, and administration route, can offer meaningful benefit while the regulated pharmaceutical pipeline catches up. For many of my patients in Boston and across the state, the answer to that question has already been yes.
I have been practicing cannabis medicine for over two decades and treating patients with chronic low back pain for the entirety of that time. What the VER-01 data describes, patients who experience significant pain reduction without the downstream harms of opioid dependence, is something I see reflected in clinical experience across thousands of patients. The mechanism is not mysterious. The endocannabinoid system modulates nociception, inflammation, and sleep through well-characterized pathways. What has been missing is not the science; it has been the political and regulatory will to produce the evidence at the scale that regulatory bodies require.
The FDA Breakthrough Therapy Designation for VER-01 is the most significant single regulatory event in cannabis medicine I have seen. It does not mean the conversation is finished. It means the conversation has finally moved to the right venue. Patients should not read this as permission to self-medicate, and clinicians should not read it as a signal to wait for the pharmaceutical product before engaging with plant medicine. What it means is that the evidence has crossed a threshold the agency takes seriously, and that changes the professional and ethical landscape for everyone in this field. I expect this designation to accelerate conversations about insurance coverage, physician prescribing authority, and hospital formulary access in ways that will matter to patients long before VER-01 reaches a US pharmacy shelf.
What a Careful Reader Should Take Away
VER-01’s designation is a landmark, and it deserves to be treated as one. At the same time, it is worth being clear about what patients with chronic back pain can do today. The Massachusetts Medical Use of Marijuana Program provides a legal, clinician-supervised pathway to medical cannabis for qualifying patients. Chronic pain is among the most common qualifying conditions. Working with a physician experienced in cannabis medicine to identify the right formulation, dose, and route of administration remains the most direct path to meaningful relief.
The VER-01 story adds confidence to the underlying biology. It does not replace the need for individualized clinical judgment. Pain is personal, and the endocannabinoid system responds differently across patients depending on genetics, prior exposure, co-morbidities, and a range of other factors. The designation tells us the general direction is right. Getting patients to the right place still requires a physician who understands the terrain.
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Kindred M, et al. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial. Nature Medicine. 2025; doi: 10.1038/s41591-025-03977-0. Available at: nature.com
VERTANICAL. FDA Grants Breakthrough Therapy Designation to VER-01. Press release, May 18, 2026. Additional coverage: The Marijuana Herald
Frequently Asked Questions
What is FDA Breakthrough Therapy Designation and why does it matter?
FDA Breakthrough Therapy Designation is a formal program designed to expedite the development and review of drugs that may offer a substantial improvement over existing therapies for a serious or life-threatening condition. Receiving the designation means the FDA will provide intensive guidance during development, rolling review of submitted data, and faster overall review timelines. It is not the same as approval, but it signals the agency considers the preliminary clinical evidence genuinely compelling. For VER-01, it means the FDA looked at two Phase 3 RCTs for chronic low back pain and decided this treatment deserves priority attention.
What is VER-01 and how is it different from other cannabis products?
VER-01 is a standardized, pharmaceutical-grade full-spectrum extract derived from a proprietary Cannabis sativa strain designated DKJ127 L., developed by VERTANICAL, a subsidiary of the FUTRUE Group. It contains a defined, consistent mixture of cannabinoids, terpenes, and other bioactive compounds across every production batch. This is fundamentally different from dispensary cannabis products, which vary considerably in composition depending on the cultivar, harvest conditions, and extraction method. VER-01’s pharmaceutical standardization is what allowed it to be tested in a rigorous Phase 3 RCT and what makes its safety and efficacy data specific to this formulation only.
Is VER-01 available in the United States right now?
No. VER-01 is not yet available in the United States. VERTANICAL is currently running a separate pivotal Phase 3 trial in the US, with initial data expected in 2027. If results are positive, the company plans to submit a New Drug Application to the FDA in 2028. Marketing authorization in Europe is expected first, within weeks of the Breakthrough Therapy Designation announcement in May 2026. US patients interested in cannabis for chronic pain can currently access medical cannabis through state-licensed programs, but VER-01 itself is not part of those programs.
How did VER-01 compare to opioids in clinical trials?
In a direct Phase 3 comparison study, VER-01 produced greater pain reduction than opioids while also demonstrating better gastrointestinal tolerability. Critically, patients in the VER-01 arm showed no evidence of dependence or withdrawal on discontinuation, in contrast to the well-documented addiction liability of opioid therapy. This does not mean VER-01 is risk-free; adverse events were reported in 83.3% of VER-01 participants, primarily dizziness, fatigue, and nausea. However, these events were predominantly mild to moderate, self-limiting, and declined rapidly after the initial dose-titration period.
Is VER-01 addictive?
Based on the Phase 3 trial data reported by VERTANICAL, VER-01 showed no evidence of dependence or withdrawal in participants who discontinued the treatment. This is a meaningful safety signal given the opioid crisis context and represents one of the key advantages cited in the FDA Breakthrough Therapy Designation. Long-term post-marketing data will be needed to fully characterize the dependence profile, as is standard for any new therapeutic, but the Phase 3 evidence is encouraging on this point.
What are the side effects of VER-01?
Treatment-emergent adverse events were reported in 83.3% of VER-01 participants versus 67.3% in the placebo group. The most common side effects were dizziness, fatigue, and nausea. The trial investigators noted that these were predominantly mild to moderate in severity, occurred primarily during the initial dose-titration phase, were self-limiting, and declined markedly within the first days of treatment. The overall intensity of adverse effects was described as comparable to placebo. No serious safety signals related to dependence or organ toxicity were reported.
Can I use medical cannabis for chronic back pain right now in Massachusetts?
Yes. Chronic pain is a qualifying condition under the Massachusetts Medical Use of Marijuana Program, and Massachusetts patients with appropriate physician certification can access medical cannabis from licensed dispensaries. The cannabis available through this program is not VER-01 and will vary in formulation and quality, which is why working with a physician experienced in cannabis medicine to identify the right product, dose, and route of administration matters. CED Clinic physicians in Boston and across Massachusetts work with patients to navigate these decisions based on their specific pain profile, co-morbidities, and medication history.
What does “full-spectrum” mean and why does it matter for pain treatment?
A full-spectrum cannabis extract contains a broad range of the plant’s naturally occurring compounds, including multiple cannabinoids (THC, CBD, CBG, CBN, and others), terpenes, and other bioactive constituents, rather than a single isolated compound like pure CBD. Research suggests that these compounds may work synergistically through what is sometimes called the “entourage effect,” potentially producing therapeutic effects that a single isolated molecule would not. VER-01’s full-spectrum composition, derived from a specific strain selected for its pain-relevant phytochemical profile, is central to its mechanism of action and distinguishes it from single-molecule cannabis-derived drugs like Epidiolex.
How does this FDA designation relate to cannabis rescheduling?
The FDA Breakthrough Therapy Designation for VER-01 and the DEA’s ongoing rescheduling process are separate regulatory pathways, but they are occurring simultaneously and reinforce each other’s momentum. The DOJ recently issued a final order moving FDA-approved and state-legal cannabis products to Schedule III, with an administrative hearing scheduled for June 29, 2026, to advance the process for all cannabis. The Breakthrough Therapy Designation signals that the FDA is prepared to engage seriously with cannabis-derived therapeutics, which strengthens the scientific and regulatory argument for rescheduling. Both developments point in the same direction: formal institutional recognition of cannabis medicine is accelerating.
What should I ask my doctor about cannabis for chronic back pain?
Start by asking whether your physician has experience with medical cannabis and can guide you through the Massachusetts certification process. Then ask about formulation: the ratio of THC to CBD, whether a full-spectrum or broad-spectrum product is appropriate for your situation, and whether topical, oral, or inhaled delivery makes the most sense for your type of pain. Ask about drug interactions, particularly if you take medications that are metabolized by cytochrome P450 enzymes, and about the starting dose and titration schedule. VER-01 is not available yet, but your physician can help you access the best current options while the pharmaceutical pipeline catches up.
